![Julie Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Smith
Direttore/Membro del Consiglio presso
EXELIXIS, INC.
Patrimonio netto: 1 M $ in data 31/05/2026
Profilo
Julie Anne Smith is currently an Independent Director at Exelixis, Inc. since 2016 and an Independent Director at Stoke Therapeutics, Inc. since 2020.
Former roles include President, Chief Executive Officer & Director at Horizon Pharmaceutical LLC; President & Chief Executive Officer at Raptor Pharmaceuticals, Inc. from 2015 to 2016; President, Chief Executive Officer & Director at Nuredis, Inc. from 2017 to 2018; Chief Executive Officer & Director at Nuvig Therapeutics, Inc.; President, Chief Executive Officer & Director at ESCAPE Bio, Inc. from 2018 to 2022; Director-Channel Strategy & Design at Bristol Myers Squibb Co.; Director-Health & Emerging Companies Sections at Biotechnology Innovation Organization; Independent Director at Astellas Gene Therapies, Inc. from 2016 to 2020; Vice President-Commercial at Jazz Pharmaceuticals, Inc. from 2006 to 2008; Vice President-Global Marketing at Genzyme General from 2001 to 2005; Head-Operations & Business Development at Novazyme Pharmaceuticals, Inc. from 2000 to 2001; and Chief Commercial Officer & Vice President at Enobia Pharma, Inc. from 2008 to 2012.
Education includes undergraduate studies at Cornell University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
EXELIXIS, INC. 0,01% | 27/05/2026 | 28.957 ( 0,01% ) | 1 M $ | 31/05/2026 |
| 03/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Posizioni attive di Julie Smith
| Società | Posizione | Inizio |
|---|---|---|
| EXELIXIS, INC. | Direttore/Membro del Consiglio | 22/09/2016 |
| STOKE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 04/06/2020 |
Precedenti posizioni note di Julie Smith
| Società | Posizione | Fine |
|---|---|---|
ESCAPE Bio, Inc.
 ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease | Amministratore Delegato | 01/08/2022 |
| AUDENTES THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 15/01/2020 |
Nuredis, Inc.
 Nuredis, Inc. BiotechnologyHealth Technology Develops treatments for neurodegenerative and neuromuscular diseases | Amministratore Delegato | 01/06/2018 |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and markets life-altering therapeutics | Amministratore Delegato | 01/10/2016 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for bone disorders | Corporate Officer/Principal | 01/05/2012 |
Formazione di Julie Smith
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
56
Relazioni di 1° grado
15
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 15 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Genzyme General
 Genzyme General Medical SpecialtiesHealth Technology Develops and markets specialty therapeutic, surgical, and diagnostic products | Health Technology |
Novazyme Pharmaceuticals, Inc.
 Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Researches and develops methods for modifying recombinantly produced enzymes | Commercial Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for bone disorders | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of life-altering therapeutics that treat debilitating and often fatal diseases | Health Technology |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and markets life-altering therapeutics | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
Stoke Therapeutics, Inc.
 Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease | Health Technology |
Nuredis, Inc.
Nuredis, Inc. BiotechnologyHealth Technology Develops treatments for neurodegenerative and neuromuscular diseases | Health Technology |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops translating novel therapeutics medicine for autoimmune diseases | Health Technology |
